Samuele Marro, PhD
- ASSISTANT PROFESSOR | Neuroscience
Research Topics:
Autism, Induced pluripotent stem cells, Neuroscience, Synaptic PlasticityI received my PhD in Human Biology from the Molecular Biotechnology Center at the University of Torino in Italy. I was trained as a postdoctoral fellow in pluripotent stem cell biology in the laboratory of Marius Wernig, MD PhD, at the Institute for Stem Cell Biology and Regenerative Medicine at Stanford University.
I am currently an Assistant Professor in the Nash Family Department of Neuroscience and the Black Family Stem Cell Institute at the Icahn School of Medicine at Mount Sinai.
My team focuses on synaptic plasticity and its dysfunction in Fragile X syndrome, the number one genetic cause of autism. As a tool, the group uses human neurons directly differentiated from pluripotent stem cells and genetically modified using CRISPR/Cas9 tools.
I also serve as co-Director of the Stem Cell Engineering Core. This institutional Core provides services at a reduced cost to the Icahn School of Medicine community. Services include the derivation of iPS from patient blood samples, iPS differentiation into specific cell types, and gene-editing in iPS to create or repair putative disease mutations.
Multi-Disciplinary Training Areas
Development, Regeneration, and Stem Cells [DRS], Neuroscience [NEU]Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Marro did not report having any of the following types of financial relationships with industry during 2019 and/or 2020: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.